Neogen Corporation $NEOG Shares Bought by Mackenzie Financial Corp
Mackenzie Financial Corp increased its stake in Neogen Corporation by 0.7% in Q2, owning 3.60% of the company. Neogen's stock opened at $5.98 with a market cap of $1.30 billion. Analysts have mixed ratings, with an average "Hold" rating and a price target of $8.83. Neogen develops products for food and animal safety.
Mackenzie Financial Corp increased its stake in Neogen Corporation (NASDAQ:NEOG - Free Report) by 0.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,813,079 shares of the company's stock after purchasing an additional 54,590 shares during the quarter. Mackenzie Financial Corp owned about 3.60% of Neogen worth $37,347,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of NEOG. Caitong International Asset Management Co. Ltd lifted its stake in shares of Neogen by 388.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 10,071 shares of the company's stock worth $87,000 after acquiring an additional 8,010 shares during the period. Savant Capital LLC acquired a new position in shares of Neogen in the 2nd quarter worth approximately $50,000. Blue Trust Inc. lifted its stake in Neogen by 181.7% during the second quarter. Blue Trust Inc. now owns 11,974 shares of the company's stock valued at $57,000 after purchasing an additional 7,724 shares during the last quarter. United Services Automobile Association bought a new stake in Neogen during the first quarter worth approximately $112,000. Finally, Walleye Trading LLC bought a new stake in Neogen during the first quarter worth approximately $118,000. Institutional investors own 96.73% of the company's stock.
Neogen Stock Performance
Shares of NEOG stock opened at $5.98 on Monday. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -1.25 and a beta of 1.90. Neogen Corporation has a 1-year low of $3.87 and a 1-year high of $14.33. The company has a current ratio of 3.58, a quick ratio of 2.26 and a debt-to-equity ratio of 0.37. The stock's fifty day simple moving average is $5.98 and its 200-day simple moving average is $5.61.
Wall Street Analyst Weigh In
NEOG has been the subject of a number of recent research reports. CJS Securities started coverage on Neogen in a research report on Monday, September 29th. They set a "market perform" rating and a $10.00 price objective for the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Neogen in a report on Tuesday, November 25th. Wall Street Zen lowered Neogen from a "buy" rating to a "hold" rating in a research report on Sunday, November 9th. Zacks Research upgraded Neogen from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 20th. Finally, Piper Sandler set a $6.50 price objective on shares of Neogen and gave the company a "neutral" rating in a research note on Thursday, October 16th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $8.83.
Get Our Latest Report on NEOG
Neogen Company Profile
(Free Report)Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.
See Also
- Five stocks we like better than Neogen
- What is the Dogs of the Dow Strategy? Overview and Examples
- Worried About Inflation? These 3 ETFs Offer Real Protection
- Where to Find Earnings Call Transcripts
- Intel’s Black Friday Breakout: Apple Rumors Fuel a Holiday Rally
- Investing in the High PE Growth Stocks
- Klarna's Crypto Play: A Plan to Fix Its Profit Problem
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Neogen Right Now?
Before you consider Neogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neogen wasn't on the list.
While Neogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
